Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

(OP:RHHBY)

52.23 UNCHANGED
Streaming Delayed Price Updated: 9:48 AM EDT, Jun 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 84,456
Open 52.20
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close -
Today's Range 52.14 - 52.25
52wk Range N/A - N/A
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Will SpaceX Stock Double Anytime Soon? No -- but These 3 Stocks Could ↗
These stocks are better bets to skyrocket than the much-hyped rocket stock. 
Via The Motley Fool
News headline image
Jazz Pharmaceuticals' Lung Cancer Drug Setback in Late-Stage Trials: Here's Why the Stock Impact May Be More Limited Than It Looks ↗
The long-term thesis remains largely unchanged. 
Via The Motley Fool

Performance

More News

Read More
MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Novel Multiple Sclerosis Therapy Toward Phase 2 Trials
Via Investor Brand Network
Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis
Via Investor Brand Network
News headline image
Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis
From BioMedWire
Via GlobeNewswire
News headline image
Teva Just Delivered More Good News on Its Biggest Growth Driver. Is the Stock Still a Bargain? ↗
Via The Motley Fool
News headline image
FDA Accepts Supplemental Biologics License Application for Genentech’s Lunsumio and Polivy Combination for People With Relapsed or Refractory Large B-Cell Lymphoma
From Genentech
Via Business Wire
News headline image
FDA Grants Priority Review for Genentech’s Tecentriq for a Certain Type of Stage III Colon Cancer
From Genentech
Via Business Wire
News headline image
IXUS vs. IEFA: Which International ETF Is Better for Most Investors? ↗
Via The Motley Fool
Topics ETFs
News headline image
FDA Accepts New Drug Application for Genentech’s Giredestrant in ER-Positive Early-Stage Breast Cancer, the First and Only Oral SERD With Positive Phase III Results in the Curative Setting
From Genentech
Via Business Wire
News headline image
Genentech to Present New Data Advancing Its Obesity Portfolio at the American Diabetes Association’s 2026 Scientific Sessions
From Genentech
Via Business Wire
News headline image
President Trump's Drug Pricing Policies Could Hurt Drugmakers' Profits. Time to Sell Pharma Stocks? ↗
Via The Motley Fool
Topics Economy Government
News headline image
Recursion Pharmaceuticals Just Hit a 52-Week Low. Is This Former Nvidia Holding a Smart Buy Now? ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Genentech to Present New Data at ASCO 2026, Reinforcing Giredestrant's Potential to Transform the Treatment Paradigm in Early Breast Cancer
From Genentech
Via Business Wire
News headline image
3 International ETFs for Investors Looking Beyond U.S. Stocks ↗
Via The Motley Fool
Topics Artificial Intelligence ETFs
News headline image
Eli Lilly Stock: Next Stop $2,000? ↗
Via The Motley Fool
News headline image
Genentech to Present Extensive Data Showcasing Its Industry-Leading Ophthalmology Portfolio at ARVO 2026
From Genentech
Via Business Wire
News headline image
Genentech Partners With Comedy Icon Damon Wayans and diaTribe to Address Diabetes-Related Vision Loss With ‘All Eyes on DME’ Campaign
From Genentech
Via Business Wire
BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Leads Shift Toward Pipeline-Driven Valuation in Biotech Sector
Via Investor Brand Network
Topics Intellectual Property
News headline image
Genentech’s Fenebrutinib Significantly Reduced Relapses Versus Standard of Care to Approximately One Every 17 Years in RMS
From Genentech
Via Business Wire
News headline image
Advancing Drug Pipelines Drive Biotech Valuations as Scientific Progress Gains Financial Recognition
From BioMedWire
Via GlobeNewswire
News headline image
Genentech’s Enspryng (Satralizumab) Reduces Risk of Relapses by 68% Demonstrating Potential to Become First Treatment for MOGAD
From Genentech
Via Business Wire
News headline image
FDA Accepts Application for Genentech’s Gazyva for the Treatment of the Most Common Form of Lupus
From Genentech
Via Business Wire
News headline image
Could AbbVie Crash Lilly's Weight‑Loss Party? ↗
Via The Motley Fool
News headline image
The Science of Scale: An In-Depth Look at Regeneron Pharmaceuticals (REGN) in 2026
Via Finterra
Topics Earnings Economy Intellectual Property

Frequently Asked Questions

Is RHHBY publicly traded?
Yes, RHHBY is publicly traded.
What exchange does RHHBY trade on?
RHHBY trades on the OTC Traded
What is the ticker symbol for RHHBY?
The ticker symbol for RHHBY is RHHBY on the OTC Traded
What is the current price of RHHBY?
The current price of RHHBY is 52.23
When was RHHBY last traded?
The last trade of RHHBY was at 06/29/26 09:48 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.